Burden of disease – WHO criteria
Burden of disease conceptBurden of disease – concept• Burden of disease definition: The impact of premature
mortality and disability due to a given medical conditionB d f di i l l t d i di bilit dj t d • Burden of disease is calculated using disability-adjusted life years (DALY)
• DALY is a composite measure of premature mortality d di bilit i l t t f h lth lif l t d and disability, equivalent to years of healthy life lost due
to a given condition• DALY, thus, represent the sum of years of life lost (YLL)
d li d ith di bilit (YLD)and years lived with disability (YLD)• Discrepancies in study outcomes arise because either of
two methods of calculating disability weights can be emplo edemployed
2
Burden of Disease (BoD) Related to Parkinson’s Disease in Spain in the
Burden of disease
Parkinson s Disease in Spain in the Year 2000
E. Cubo et al.
Burden of diseaseGeneva: World Health Organization 2001
Based on the WHO BoD study in 2000, PD DALY contributed: • 0.1% of the Global Burden of Disease (GBD) in the world• 0 6% in the European A subregion• 0.6% in the European A subregion• 0.5% of the GBD in Spain
In accordance with such data for the European A subregion, in Spain, PD represented approximately 1/200 of the GBD lower than the represented approximately 1/200 of the GBD, lower than the corresponding figures for other frequent ageing-related diseases such as dementia (8/200) and cerebrovascular disease (12/200)
To view abstract, click Abstracts link above 3
NMS questionnaire – symptom prevalence
NMS questionnaireNMS questionnaire
Average NMS per patient = 10
(as per the NMS Quest; n = 525)
% indicates % patients with NMS
AAMemory: apathy/attention/memory
Martinez-Martin et al. Mov Disord 2007;22:1623–29.
% indicates % patients with NMS
5
Non-Motor Symptom scale –
symptom severitycore
NMS scale
symptom severityN
MS
S T
ota
l sc
.01
NMS scaleHaehn & Yahr-based severity levels
.00
5
Den
sity
0
0 50 100 150 200 250
Total NMSS
Non-Motor Symptom Scale score = 56.5 ± 40.7
( 242)
Severity of NMS increased with increasing disease severity.
(n= 242)
Chaudhuri et al. Mov Disord 2007;22:1901–11.
y g ySleep-Fatigue was the NMSS domain with highest (standardized) severity score.
6
Only symptoms which were
Patient reported
Only symptoms which were expressed by greater than 10% of patients are listed n = 123
symptomsA total of 90 different symptoms
were reported by patients. This list accounted for 1551
(88.3%) of the total symptom count
21 of these 32 symptoms (65.6%) were NMS
Lee et al. Parkinsonism Relat Disord 2007;13:284–9.
7
Of the symptoms reported: • 948 (54.0%) were simply present• 526 (29.9%) were having a moderate affect on the day ( ) g y• 283 (16.1%) were having a dominating affect on the day
The 10 most common symptoms that PD patients reported were dominating their day
Frequency of symptoms
do a g day
7 of these 10 symptoms (70%) were NMS
Lee et al. Parkinsonism Relat Disord 2007;13:284–9.
8
Non-motor fluctuations (NMF) in PD
• Most frequent NMF: anxiety (66%) drenching • Most frequent NMF: anxiety (66%), drenching sweats (64%), slowness of thinking (58%), fatigue(56%), and akathisia (54%)S h i d • Some symptoms such as anxiety or dyspnoea correlated with a greater level of disability
• Total number of NMF was found to be correlated with the motor disability
Suprisingly 28% of the patients stated that NMF Suprisingly, 28% of the patients stated that NMF involved a greater degree of disability than motor fluctuations
Witjas et al. Neurology 2002;59:408–13.
9
The many faces of BoD
BoD may be understood as the whole range of physical, mental, and socioeconomic problems experienced by patients
Health-related quality of life (HRQoL) means the
and socioeconomic problems experienced by patients
Physical, mental and social well-being
q y ( Q )
perception and evaluation by patients of the
impact on their lives caused by the
disease and its consequences. Martínez-Martín, Personal communication, 1997
Definition of healthWHO, 1947
Basic components of the HRQoLWHO, 1947 the HRQoL
Martinez-Martin et al. J Neurol 1998;245(Suppl 1):39–41.
10
Why HRQoL should be measured?
HRQ L i l t i h i di bli di th t l k HRQoL is relevant in chronic disabling diseases that lack a cure
– Main objective of caring is to improve patients’ quality of life (QoL)(Q )
• HRQoL provides unique information directly from patients
– This cannot be obtained by any other clinical method
• HRQoL is a complement to the clinical evaluation
– Focuses on aspects of interest to the patient
• HRQoL helps to understand discrepancies between doctor and • HRQoL helps to understand discrepancies between doctor and patient perceptions
– It is not equivalent to clinical measures
11
Health related QoL
Based on a literature review and consultation with HRQoL experts, five clinicians and three patients 12 areas of HRQoL were identified as
• Physical function • Communication
clinicians and three patients, 12 areas of HRQoL were identified as particularly relevant to PD:
y• Mental health/emotional
well being• Self-image• Social function
• Sleep and rest• Eating• Role function• Energy/fatigue
Those highlighted represent the areas associated with non-motor symptoms.
• Health-related distress • Cognitive function
Energy/fatigue• Sexual function
Damiano et al. Qual Life Res 1999;8:235–43.
To view abstract, click Abstracts link above 12
Review MJ Forjaz B Frades P Martinez-MartinMJ Forjaz, B Frades, P Martinez-Martin
R i f 56 t di HRQ L i PD t f d l • Review of 56 studies on HRQoL in PD not focused on scale validation or effect of treatments
• Average sample size: 179 ± 174 patients (range: 21–902 g p p ( gpatients)
• Only summary indexes or total scores were considered
Forjaz et al. Rev Neurol (Accepted 2009).
13
HRQoL determinants and associated factors
M t if t tiMotor manifestations• Motor impairment• Gait disorder• Dyskinesias and fluctuations• Dyskinesias and fluctuations• Axial manifestations• Tremor
NMS• Fatigue• Sleep disturbances• Pain • Sweating• Nausea• Orthostatism
Forjaz et al. Rev Neurol (Accepted 2009).
14
Quality of life and depression in PD
Anette Schrag
While the association between PD and reduced HRQoL is greater in advanced disease stages there is no close relationship between
g
advanced disease stages, there is no close relationship between disease duration and impact on QoL, and the relationship between clinical rating scales and HRQoL scores is only moderate. On the other hand, the presence and severity of depression in PD t l l t ith HRQ L d b f t di h strongly correlates with HRQoL scores, and a number of studies have
reported depression as the main determinant of poor HRQoL scores
Schrag et al. J Neurol Sci 2006;248:151–7.
15
What contributes to QoL in patients with PD?
Anette Schrag, Marjan Jahanshahi, Niall Quinng, j , Q
Conclusion— Depression, disability, postural instability, and cognitive impairment have the greatest influence on QoL in PD.
Schrag et al. J Neurol Neurosurg Psychiatry 2000;69:308–12.
16
Question 1. On average, how many non-motor symptoms does each patient with PD experience?symptoms does each patient with PD experience?
A) 5A) 5
B) 10
C) 15C) 15
Correct - Click anywhere to Incorrect - Click anywhere to Correct Click anywhere to continue
Incorrect Click anywhere to try again
You must answer the Incorrect please try againYou must answer the question before continuing
SubmitSubmit ClearClearIncorrect, please try again
17
Question 2. What proportion of the 10 most common symptoms that patients with PD report to dominate h dtheir day are non-motor symptoms?
A) 20%A) 20%
B) 50%
C) 70%C) 70%
Correct - Click anywhere to Incorrect - Click anywhere to Correct Click anywhere to continue
Incorrect Click anywhere to try again
Incorrect please try againYou must answer the Incorrect, please try againYou must answer the question before continuing
SubmitSubmit ClearClear
18
Question 3. What is the main factor reported to be associated with poor HRQoL in patients with PD?associated with poor HRQoL in patients with PD?
A) SleepinessA) Sleepiness
B) Depression
C) AnxietyC) Anxiety
Correct - Click anywhere to Incorrect - Click anywhere to Correct Click anywhere to continue
Incorrect Click anywhere to try again
Incorrect please try againYou must answer the Incorrect, please try againYou must answer the question before continuing
SubmitSubmit ClearClear
19
Copyright statements
Slide 4 ©2006 reproduced with permission from Slide 4 ©2006, reproduced with permission from Elsevier
Slide 5 ©2007, reproduced with permission from John Wil d S IWiley and Sons, Inc
Slide 7 ©2007, reproduced with permission from Elsevier
Slide 8 ©2007, reproduced with permission from Elsevier
Slide 16 ©2000, reproduced with permission from the © , p pBMJ Publishing Group
20